AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

News provided by

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Mar 04, 2020, 21:37 ET

NORTH CHICAGO, Ill., March 4, 2020 /PRNewswire/ -- AbbVie issued the following form today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing (Note 1)	Edward J. Rapp
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	3 March 2020



2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	33,537 Common Shares (0.00002%)
(2) Derivatives (other than options)	16,872 Stock Equivalent Units
(3) Options and agreements to purchase/sell	N/A
Total	50,409 (0.00003%)



(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total



3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase by spouse in trust	2,875 common shares	$87.87



(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)



(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)



(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.



Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	3 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.